1
|
Troncoso LL, Pontillo A, Oliveira EMLD, Finkelszteijn A, Schneider S, Chies JAB. CCR5Δ32 - A piece of protection in the inflammatory puzzle of multiple sclerosis susceptibility. Hum Immunol 2018; 79:621-626. [PMID: 29729320 DOI: 10.1016/j.humimm.2018.04.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 04/25/2018] [Accepted: 04/26/2018] [Indexed: 01/08/2023]
Abstract
BACKGROUND Leucocyte infiltration and activation in the central nervous system (CNS) is an important step in the pathogenesis of multiple sclerosis (MS). The Chemokine receptor 5 (CCR5) is implicated in immune cell migration and cytokine release in the CNS, and it was demonstrated to strongly contribute to CNS inflammation and damage in several models of sterile and pathogen-mediated CNS diseases. Although the inhibition of CCR5 results in a beneficial effect in experimental models of MS, conflicting results have been found about the loss-of-function variant CCR5Δ32 (rs333) in MS patients. The aim of this study was to evaluate the association of CCR5Δ32 and MS in a Brazilian case/control cohort. PATIENTS AND METHODS 261 MS patients and 435 healthy controls were genotyped for CCR5Δ32. Allelic and genotypic frequencies were compared between patients and controls (case/control analysis), and among patients classified according to the MS clinical form (relapsing remitting versus progressive) and severity (EDSS, MSSS and progression index). RESULTS AND DISCUSSION The CCR5Δ32 variant frequency was statistically higher in controls as compared to patients presenting European-derived ethnic background. The variant was more frequent in progressive MS as compared to RR-MS patients, and, although not statistically significant, a higher frequency of the truncated allele was observed among patients with less severe forms of MS. These findings emphasize the potential involvement of CCR5 signaling in CNS inflammation and damage in MS. CONCLUSION The CCR5Δ32 deletion is a protective factor against the development and progression of MS in European-derived Brazilian patients.
Collapse
Affiliation(s)
- Lian Lopes Troncoso
- Laboratório de Imunobiologia e Imunogenética, Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
| | - Alessandra Pontillo
- Universidade de São Paulo, Instituto de Ciências Biomédicas, Departamento de Imunologia, São Paulo, SP, Brazil
| | - Enedina Maria Lobato de Oliveira
- Ambulatório de Doenças Desmielinizantes da disciplina de Neurologia, Escola, Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
| | | | | | - José Artur Bogo Chies
- Laboratório de Imunobiologia e Imunogenética, Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
| |
Collapse
|
2
|
Criscuolo C, Carbone R, Lieto M, Peluso S, Guacci A, Filla A, Quarantelli M, Lanzillo R, Brescia Morra V, De Michele G. SPG5 and multiple sclerosis: clinical and genetic overlap? Acta Neurol Scand 2016; 133:410-4. [PMID: 26370385 DOI: 10.1111/ane.12476] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/17/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND Autosomal recessive (AR) spastic paraplegia type 5 (SPG5) is due to mutations in the CYP7B1 gene, encoding for the cytochrome P450-7B1, responsible for oxysterols 7α-hydroxylation. Oxysterol/cholestenoic acids pool plays a role in motor neuron survival and immune response. SPG5 is characterized by white matter abnormalities at brain resonance imaging (MRI). In view of clinical presentation and MRI findings, multiple sclerosis (MS) is a possible differential diagnosis of SPG5. This study aimed to evaluate the frequency of CYP7B1 mutations in patients with MS. METHODS One hundred and seventeen MS patients with clinical spastic paraplegia or possible AR transmission were selected for the mutational screening. RESULTS Forty-three patients had primary progressive, 26 relapsing remitting, 26 secondary progressive, and 22 relapsing progressive MS clinical course. No CYP7B1 homozygous mutations were identified. Two novel variants and one pathogenic mutation were found at heterozygous state. CONCLUSIONS The two novel variants cosegregated with pyramidal signs and autoimmune diseases suggesting that they might be susceptibility factors. Reduced cytochrome P450-7B1 enzymatic activity could alter the balance among neurotoxic and neuroprotective oxysterols promoting motor neuron degeneration and/or immune response.
Collapse
Affiliation(s)
- C. Criscuolo
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - R. Carbone
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - M. Lieto
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - S. Peluso
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - A. Guacci
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - A. Filla
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - M. Quarantelli
- Biostructure and Bioimaging Institute; National Research Council; Naples Italy
| | - R. Lanzillo
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - V. Brescia Morra
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| | - G. De Michele
- Department of Neurosciences, Reproductive Sciences and Odontostomatology; ‘Federico II’ University of Naples; Naples Italy
| |
Collapse
|
3
|
Martin-Blondel G, Brassat D, Bauer J, Lassmann H, Liblau RS. CCR5 blockade for neuroinflammatory diseases — beyond control of HIV. Nat Rev Neurol 2016; 12:95-105. [DOI: 10.1038/nrneurol.2015.248] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
4
|
Jin Q, Chen H, Wang X, Zhao L, Xu Q, Wang H, Li G, Yang X, Ma H, Wu H, Ji X. The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection. PLoS One 2015; 10:e0131894. [PMID: 26154172 PMCID: PMC4496087 DOI: 10.1371/journal.pone.0131894] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2014] [Accepted: 06/08/2015] [Indexed: 12/03/2022] Open
Abstract
Background Insertion of T4 lysozyme (T4L) into the GPCR successfully enhanced GPCR protein stability and solubilization. However, the biological functions of the recombinant GPCR protein have not been analyzed. Methods We engineered the CCR5-T4L mutant and expressed and purified the soluble recombinant protein using an E.coli expression system. The antiviral effects of this recombinant protein in THP-1 cell lines, primary human macrophages, and PBMCs from different donors were investigated. We also explored the possible mechanisms underlying the observed antiviral effects. Results Our data showed the biphasic inhibitory and promotion effects of different concentrations of soluble recombinant CCR5-T4L protein on R5 tropic human immunodeficiency virus-1 (HIV-1) infection in THP-1 cell lines, human macrophages, and PBMCs from clinical isolates. We demonstrated that soluble recombinant CCR5-T4L acts as a HIV-1 co-receptor, interacts with wild type CCR5, down-regulates the surface CCR5 expression in human macrophages, and interacts with CCL5 to inhibit macrophage migration. Using binding assays, we further determined that recombinant CCR5-T4L and [125I]-CCL5 compete for the same binding site on wild type CCR5. Conclusions Our results suggest that recombinant CCR5-T4L protein marginally promotes HIV-1 infection at low concentrations and markedly inhibits infection at higher concentrations. This recombinant protein may be helpful in the future development of anti-HIV-1 therapeutic agents.
Collapse
Affiliation(s)
- Qingwen Jin
- Department of Microbiology and Immunology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu Province, China
- Department of Neurology, The People’s Hospital of Jiangsu Province, 300 Guangzhou Road, Nanjing, Jiangsu Province, China
- Department of Neurology, Nanjing First Hospital, 68 Changle Road, Nanjing, Jiangsu Province, China
| | - Hong Chen
- Department of Neurology, The People’s Hospital of Jiangsu Province, 300 Guangzhou Road, Nanjing, Jiangsu Province, China
| | - Xingxia Wang
- Department of Neurology, The People’s Hospital of Jiangsu Province, 300 Guangzhou Road, Nanjing, Jiangsu Province, China
| | - Liandong Zhao
- Department of Neurology, The Second Hospital of Huaian, 62 Huaihai South Road, Huaian, Jiangsu Province, China
| | - Qingchen Xu
- Department of Neurology, Nanjing First Hospital, 68 Changle Road, Nanjing, Jiangsu Province, China
| | - Huijuan Wang
- Department of Microbiology and Immunology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu Province, China
| | - Guanyu Li
- Department of Neurology, Mingji Hospital of Nanjing, Jiangsu Province, 71 Riverside West Road, Nanjing, Jiangsu Province, China
| | - Xiaofan Yang
- Department of Microbiology and Immunology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu Province, China
| | - Hongming Ma
- Department of Biomedical Sciences, Texas Tech University Health Sciences Center, 5001 El Paso Drive, El Paso, Texas, United States of America
| | - Haoquan Wu
- Department of Biomedical Sciences, Texas Tech University Health Sciences Center, 5001 El Paso Drive, El Paso, Texas, United States of America
| | - Xiaohui Ji
- Department of Microbiology and Immunology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu Province, China
- * E-mail:
| |
Collapse
|
5
|
Corvol JC, Devos D, Hulot JS, Lacomblez L. Clinical implications of neuropharmacogenetics. Rev Neurol (Paris) 2015; 171:482-97. [PMID: 26008819 DOI: 10.1016/j.neurol.2015.04.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Accepted: 04/24/2015] [Indexed: 01/24/2023]
Abstract
INTRODUCTION Pharmacogenetics aims to identify the underlying genetic factors participating in the variability of drug response. Indeed, genetic variability at the DNA or RNA levels can directly or indirectly modify the pharmacokinetic or the pharmacodynamic parameters of a drug. The ultimate aim of pharmacogenetics is to move towards a personalised medicine by predicting responders and non-responders, adjusting the dose of the treatment, and identifying individuals at risk of adverse drug effects. METHODS A literature research was performed in which we reviewed all pharmacogenetic studies in neurological disorders including neurodegenerative diseases, multiple sclerosis, stroke and epilepsy. RESULTS Several pharmacogenetic studies have been performed in neurology, bringing insights into the inter-individual drug response variability and in the pathophysiology of neurological diseases. The principal implications of these studies for the management of patients in clinical practice are discussed. CONCLUSION/DISCUSSION Although several genetic factors have been identified in the modification of drug response in neurological disorders, most of them have a marginal predictive effect at the single gene level, suggesting mutagenic interactions as well as other factors related to drug interaction and disease subtypes. Most pharmacogenetic studies deserve further replication in independent populations and, ideally, in pharmacogenetic clinical trials to demonstrate their relevance in clinical practice.
Collapse
Affiliation(s)
- J-C Corvol
- Sorbonne universités, UPMC université Paris 06, 4, place Jussieu, 75005 Paris, France; CIC_1422, département des maladies du système nerveux, hôpital Pitié-Salpêtrière, AP-HP, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France; Inserm, UMR_S1127, ICM, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France; CNRS, UMR_7225, ICM, 4, place Jussieu, 75005 Paris, France.
| | - D Devos
- Inserm U1171, department of movement disorders and neurology, department of medical pharmacology, university of Lille, CHU Lille, 1, place de Verdun, 59045 Lille cedex, France
| | - J-S Hulot
- Sorbonne universités, UPMC université Paris 06, 4, place Jussieu, 75005 Paris, France; Inserm, UMR_S1166, ICAN, 4, place Jussieu, 75005 Paris, France
| | - L Lacomblez
- Sorbonne universités, UPMC université Paris 06, 4, place Jussieu, 75005 Paris, France; CIC_1422, département des maladies du système nerveux, hôpital Pitié-Salpêtrière, AP-HP, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France; Inserm, UMR_S1146, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| |
Collapse
|
6
|
Török N, Molnár K, Füvesi J, Karácsony M, Zsiros V, Fejes-Szabó A, Fiatal S, Ádány R, Somogyvári F, Stojiljković O, Vécsei L, Bencsik K. Chemokine receptor V Δ32 deletion in multiple sclerosis patients in Csongrád County in Hungary and the North-Bácska region in Serbia. Hum Immunol 2014; 76:59-64. [PMID: 25500253 DOI: 10.1016/j.humimm.2014.11.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2014] [Accepted: 11/14/2014] [Indexed: 10/24/2022]
Abstract
The roles of chemokine receptor V (CCR5) and its polymorphism, rs333 in multiple sclerosis (MS) are controversial. We investigated the receptor and its deletion in a large MS (428) and a numerous control (831) population in Csongrád County (Hungary) and North-Bácska (Serbia). Taqman probes firstly were used for the allele discrimination. There was no significant difference in genotype (OR=1.092, 95% CI=0.807-1.478, p=0.568 for wt/wt (wt=wild type allele) vs wt/Δ32, Δ32/Δ32 (Δ32=Δ32 base pair deletion allele)) or allele frequency (OR=0.914, 95% CI=0.692-1.207, p=0.525). Neither the deletion nor the wt allele affected the Expanded Disability Status Scale score or the age at onset. Our results indicate no association between the CCR5 Δ32 allele and MS.
Collapse
Affiliation(s)
- Nóra Török
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Kinga Molnár
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Judit Füvesi
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Mária Karácsony
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Viktória Zsiros
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Annamária Fejes-Szabó
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Szilvia Fiatal
- Faculty of Public Health, University of Debrecen, Kassai u 26, H-4012 Debrecen, Hungary
| | - Róza Ádány
- Faculty of Public Health, University of Debrecen, Kassai u 26, H-4012 Debrecen, Hungary
| | - Ferenc Somogyvári
- Department of Medical Microbiology and Immunobiology, University of Szeged, Dóm tér 10, H-6725 Szeged, Hungary
| | - Olivera Stojiljković
- Department of Neurology, Public Hospital of Subotica, 3 Izvorska, Subotica, Serbia
| | - László Vécsei
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary; MTA-SZTE Neuroscience Research Group, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Krisztina Bencsik
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary.
| |
Collapse
|